Hormone resistance in two MCF-7 breast cancer cell lines is associated with reduced mTOR signaling, decreased glycolysis and increased sensitivity to cytotoxic drugs

Frontiers in Oncology

Volumn 4 AUG, Issue , 2014, Pages

  Leung, Euphemia ^a   Kim, Ji Eun ^a   Askarian Amiri, Marjan ^a   Joseph, Wayne R ^a   McKeage, Mark J ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Breast cancer cells; Cisplatin; Cytotoxic drugs; Estrogen receptor; mTOR; PI3K; Tamoxifen

Indexed keywords

AFIMOXIFENE; CAMPTOTHECIN; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; HYDROGEN PEROXIDE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PACLITAXEL; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ARTICLE; CELL ASSAY; CELL CYCLE; CELL PROLIFERATION ASSAY; DENSITOMETRY; DNA CONTENT; DNA DAMAGE; DRUG SENSITIVITY; ENERGY ABSORPTION; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GLUCOSE TRANSPORT; GLYCOLYSIS; HORMONE RESISTANCE; IC 50; IMMUNOBLOTTING; MCF 7 CELL LINE; MITOCHONDRIAL RESPIRATION; PHENOTYPE;

EID: 84906253941     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00221     Document Type: Article

References (33)

1. Amundson, S.A., Myers, T.G., and Fornace, A.J., Jr. (1998). Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17, 3287-3299.
2. Baguley, B.C., and Leung, E. (2011). Heterogeneity of phenotype in breast cancer cell lines. In: Gunduz M, ed. Breast Cancer Cells - carcinogenesis, cell Growth and signaling pathways.: Intech Publishers.
3. Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O'reilly, T., Natt, F., Hall, J., Lane, H.A., and Thomas, G. (2005). The mTOR inhibitor RAD001 sensitizes tumor cells to DNA damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747-759.
4. Bible, K.C., Boerner, S.A., and Kaufmann, S.H. (1999). A one-step method for protein estimation in biological samples: nitration of tyrosine in nitric acid. Anal Biochem 267, 217-221.
5. Burma, S., Chen, B.P., Murphy, M., Kurimasa, A., and Chen, D.J. (2001). ATM phosphorylates histone H2AX in response to DNA double-strand breaks. Journal of Biological Chemistry 276, 42462-42467.
6. Degraffenried, L.A., Friedrichs, W.E., Russell, D.H., Donzis, E.J., Middleton, A.K., Silva, J.M., Roth, R.A., and Hidalgo, M. (2004). Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10, 8059-8067.
7. Diehn, M., Cho, R.W., Lobo, N.A., Kalisky, T., Dorie, M.J., Kulp, A.N., Qian, D., Lam, J.S., Ailles, L.E., Wong, M., Joshua, B., Kaplan, M.J., Wapnir, I., Dirbas, F.M., Somlo, G., Garberoglio, C., Paz, B., Shen, J., Lau, S.K., Quake, S.R., Brown, J.M., Weissman, I.L., and Clarke, M.F. (2009). Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780-783.
8. Gartel, A.L., Feliciano, C., and Tyner, A.L. (2003). A new method for determining the status of p53 in tumor cell lines of different origin. Oncol Res 13, 405-408.
9. Gaur, S., Chen, L., Yang, L., Wu, X., Un, F., and Yen, Y. (2011). Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors. Cancer Lett 311, 20-28.
10. Hagenbuchner, J., Kuznetsov, A.V., Obexer, P., and Ausserlechner, M.J. (2012). BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene.
11. Hsieh, A.C., Liu, Y., Edlind, M.P., Ingolia, N.T., Janes, M.R., Sher, A., Shi, E.Y., Stumpf, C.R., Christensen, C., Bonham, M.J., Wang, S., Ren, P., Martin, M., Jessen, K., Feldman, M.E., Weissman, J.S., Shokat, K.M., Rommel, C., and Ruggero, D. (2012). The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55-61.
12. Jiang, B.H., and Liu, L.Z. (2008). Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11, 63-76.
13. Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., and Pietenpol, J.A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121, 2750-2767.
14. Leung, E., and Baguley, B.C. (2013). "mTOR signaling in endocrine resistance growth control," in The Research and Biology of Cancer. iConcept Press Ltd).
15. Leung, E., Kannan, N., Krissansen, G.W., Findlay, M.P., and Baguley, B.C. (2010). MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 9, 717-724.
16. Leung, E., Kim, J.E., Rewcastle, G.W., Finlay, G.J., and Baguley, B.C. (2011). Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther 11, 938-946.
17. Matoba, S., Kang, J.G., Patino, W.D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P.J., Bunz, F., and Hwang, P.M. (2006). p53 regulates mitochondrial respiration. Science 312, 1650-1653.
18. Miller, T.W., Balko, J.M., and Arteaga, C.L. (2011). Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29, 4452-4461.
19. Miller, T.W., Hennessy, B.T., Gonzalez-Angulo, A.M., Fox, E.M., Mills, G.B., Chen, H., Higham, C., Garcia-Echeverria, C., Shyr, Y., and Arteaga, C.L. (2010). Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120, 2406-2413.
20. Mondesire, W.H., Jian, W., Zhang, H., Ensor, J., Hung, M.C., Mills, G.B., and Meric-Bernstam, F. (2004). Targeting mammalian target of rapamycin synergistically enhances chemotherapy induced cytotoxicity in breast cancer cells. Clin Cancer Res 10, 7031-7042.
21. Murphy, M.P. (2009). How mitochondria produce reactive oxygen species. Biochem J 417, 1-13.
22. Nakano, A., Tsuji, D., Miki, H., Cui, Q., El Sayed, S.M., Ikegame, A., Oda, A., Amou, H., Nakamura, S., Harada, T., Fujii, S., Kagawa, K., Takeuchi, K., Sakai, A., Ozaki, S., Okano, K., Nakamura, T., Itoh, K., Matsumoto, T., and Abe, M. (2011). Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One 6, e27222.
23. Peskin, A.V., and Winterbourn, C.C. (2000). A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin Chim Acta 293, 157-166.
24. Saito, S., Goodarzi, A.A., Higashimoto, Y., Noda, Y., Lees-Miller, S.P., Appella, E., and Anderson, C.W. (2002). ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. Journal of Biological Chemistry 277, 12491-12494.
25. Schieber, M., and Chandel, N. (2013). ROS Links Glucose Metabolism to Breast Cancer Stem Cell and EMT Phenotype. Cancer Cell 23, 265-267.
26. Tam, K.H., Yang, Z.F., Lau, C.K., Lam, C.T., Pang, R.W., and Poon, R.T. (2009). Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 273, 201-209.
27. Thoreen, C.C., Chantranupong, L., Keys, H.R., Wang, T., Gray, N.S., and Sabatini, D.M. (2012). A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109-113.
28. Vichai, V., and Kirtikara, K. (2006). Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1, 1112-1116.
29. Vilquin, P., Villedieu, M., Grisard, E., Ben Larbi, S., Ghayad, S.E., Heudel, P.E., Bachelot, T., Corbo, L., Treilleux, I., Vendrell, J.A., and Cohen, P.A. (2013). Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer 133, 1589-1602.
30. Vivanco, I., and Sawyers, C.L. (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501.
31. Xu, R.H., Pelicano, H., Zhou, Y., Carew, J.S., Feng, L., Bhalla, K.N., Keating, M.J., and Huang, P. (2005). Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65, 613-621.
32. Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K., Kassack, M.U., Osmak, M., and Jaehde, U. (2007). Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 73, 298-307.
33. Zoncu, R., Efeyan, A., and Sabatini, D.M. (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21-35.